Director/PDMR Shareholding

RNS Number : 0885M
GlaxoSmithKline PLC
18 January 2021
 

GlaxoSmithKline plc   (the ' Company ')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthe financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

  

b)

Nature ofthe transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on Ordinary Shares held within an ISA

 

c)

Price(s)and volume(s)

Price(s)

Volume(s)

£13.9390

29

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

e)

Date ofthe transaction

2021-01-15

f)

Placeofthe transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Descriptionofthe financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

  

 

b)

Nature ofthe transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on Ordinary Shares held within an ISA

 

c)

Price(s)and volume(s)

Price(s)

Volume(s)

£13.9390

25

 

 

 

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

 

 

 

 

e)

Date ofthe transaction

2021-01-15

f)

Placeofthe transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDVLFFFFLLBBK

Companies

GSK (GSK)
UK 100